ESC 365 - The impact of early SGLT2i inclusion in quadruple therapy for de novo patients: enhancing medication management and clinical outcomes

Open Access

The impact of early SGLT2i inclusion in quadruple therapy for de novo patients: enhancing medication management and clinical outcomes

Session: Advances in cardiovascular pharmacotherapy

Topic: Antidiabetic Pharmacotherapy

Speaker: Doctor A. Esteban Fernandez (Leganes, ES)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Alberto Esteban Fernandez

Severo Ochoa Hospital, Leganes (Spain)

4 presentations

0 follower

5 more presentations in this session

Intravenous loop diuretic-induced decongestion in heart failure: an explorative study in a real-world population

Speaker: Mr M. Erhardsson (Stockholm, SE)

Incidence of erythrocytosis and thromboembolic risk in patients with heart failure and reduced ejection fraction treated with SGLT2 Inhibitors

Speaker: Doctor A. Mohamed (Copenhagen, DK)

Efficacy and safety of sotagliflozin in patients with symptomatic obstructive and non-obstructive hypertrophic cardiomyopathy (SONATA-HCM): study design

Speaker: Professor I. Olivotto (Florence, IT)

Assessing the best anticoagulation strategy for left ventricle thrombus after anterior myocardial infarction

Speaker: Doctor F. Rodrigues Santos (Viseu, PT)

Direct oral anticoagulants in patients with heart failure and atrial fibrillation: do we have an ideal score to predict major bleeding?

Speaker: Doctor V. De Simone (Legnago, IT)

Access the full session

Advances in cardiovascular pharmacotherapy

Speakers: Doctor A. Esteban Fernandez, Mr M. Erhardsson, Doctor A. Mohamed, Professor I. Olivotto, Doctor F. Rodrigues Santos...

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources